Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 0.62 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27582417 | 0.85 | GAA (0.74) | CYP1A2GAAMAPTNPC1RAB9A | |
| SCHEMBL477394 | 0.85 | CYP1A2 (0.73) | CYP1A2GAAMAPTNPC1RAB9A | |
| SCHEMBL477396 | 0.85 | CYP1A2 (0.73) | CYP1A2GAAMAPTNPC1RAB9A | |
| SCHEMBL9376091 | 0.84 | CYP1A2 (0.72) | CYP1A2GAAMAPTNPC1RAB9A | |
| SCHEMBL9376095 | 0.84 | CYP1A2 (0.72) | CYP1A2GAAMAPTNPC1RAB9A | |
| SCHEMBL10881152 | 0.84 | CYP1A2 (0.72) | CYP1A2GAAMAPTNPC1RAB9A | |
| SCHEMBL28678874 | 0.84 | CYP1A2 (0.72) | CYP1A2GAAMAPTNPC1RAB9A | |
| SCHEMBL29725061 | 0.84 | CYP1A2 (0.72) | CYP1A2GAAMAPTNPC1RAB9A | |
| SCHEMBL13784015 | 0.83 | CYP1A2 (0.71) | CYP1A2GAAMAPTNPC1RAB9A | |
| SCHEMBL25063077 | 0.83 | CYP1A2 (0.69) | CYP1A2GAAMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121085841-A | Synthesis method of 2-amino-5-fluoropyridine | 康羽生命科学技术(苏州)有限公司 | 2025-12-09 | — | — | CN | disclosed |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| CN-110092746-B | Simple preparation method of 2-amino-5-halogenated pyridine | 新发药业有限公司 | 2020-06-23 | — | — | CN | disclosed |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-1171440-A1 | SUBSTITUTED-3-CYANO-[1.7],[1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES | American Cyanamid Company (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000066583-A1 | SUBSTITUTED 3-CYANO-[1.7], [1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES | AMERICAN CYANAMID COMPANY (US) | 2000-11-09 | — | — | WO | disclosed |
| EP-0655057-B1 | CYANOGUANIDINES AS POTASSIUM CHANNEL BLOCKERS | UPJOHN CO (US) | 1997-09-17 | — | — | EP | disclosed |
| US-5567722-A | DIURETICS | THE UPJOHN COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| EP-0655057-A1 | CYANOGUANIDINES AS POTASSIUM CHANNEL BLOCKERS. | UPJOHN CO (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5371086-A | Circulatory disorders side effect reduction | THE GREEN CROSS CORPORATION (JP) | 1994-12-06 | — | — | US | disclosed |
| WO-1994004500-A1 | CYANOGUANIDINES AS POTASSIUM CHANNEL BLOCKERS | THE UPJOHN COMPANY (US) | 1994-03-03 | — | — | WO | disclosed |
| US-5262415-A | FOR TREATING DISEASES OF THE CIRCULATORY SYSTEM | THE GREEN CROSS CORPORATION (JP) | 1993-11-16 | — | — | US | disclosed |
| EP-0503627-A1 | Aminopyridine compounds | THE GREEN CROSS CORPORATION (JP) | 1992-09-16 | — | — | EP | disclosed |
| EP-0446604-A2 | Pyridine and related aza heterocycle derivatives as cardiovascular agents | AMERICAN CYANAMID COMPANY (US) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | CYP1A2 1461/4885GAA 530/4885MAPT 4456/4885 |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | HAVCR2, HCCS, EIF2AK2 | CYP1A2 1461/4885GAA 530/4885MAPT 4456/4885 |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | CYP1A2 1461/4885GAA 530/4885MAPT 4456/4885 |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | CYP1A2 1461/4885GAA 530/4885MAPT 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.